Quick Facts: Istradefylline

• Therapeutic Role: May be utilized as an adjunctive treatment.
• Primary Indication: Used alongside levodopa/carbidopa in adult patients with Parkinson's disease.
• Specific Context: Intended to address “off” episodes, which involve periods of reduced motor function.

Istradefylline is a medication authorized for use as a supplemental therapy in the management of Parkinson's disease. Its primary function is to be administered concurrently with a levodopa/carbidopa regimen in adult individuals.

The use of this medication is indicated for patients who experience motor fluctuations, commonly described as “off” episodes. These episodes are characterized by a return of symptoms such as tremor, rigidity, and slowed movement, typically occurring as the effect of other Parkinson's disease medications begins to wear off.

Incorporating istradefylline into the treatment plan is intended to help reduce the duration of these daily “off” periods. This approach offers a means to support more consistent motor control for individuals with this condition.

Who Can and Cannot Use Istradefylline?

The population eligibility for Istradefylline is defined by official regulatory documents, strictly outlining who is permitted or restricted from using the medicine.

Eligibility Scope

Eligibility-Related Restrictions

Use is conditional in certain populations. Moderate Hepatic Impairment (Child-Pugh B) restricts the maximum dosage. Heavy smokers require a higher dosage for use. Patients with a history of Dyskinesia or Psychosis require use with caution.

Istradefylline Interactions with other medicines and products

Istradefylline is primarily metabolized by the enzyme CYP3A4. Interactions may occur when it is co-administered with other medicines that affect this enzyme.

Istradefylline may also affect the levels of other medicines. Specifically, the 40 mg dose of istradefylline is a weak inhibitor of CYP3A4 and transport proteins like P-glycoprotein (P-gp). Therefore, the exposure of sensitive substrates of these systems, such as digoxin (a P-gp substrate), may increase. Patients taking istradefylline in combination with levodopa may also experience or have an exacerbation of dyskinesia. Additionally, heavy tobacco smoking (a CYP1A2 inducer) can decrease istradefylline exposure, requiring a possible dosage increase for the patient.

Istradefylline functions as a selective antagonist of the adenosine A2A receptors (A2AR). These receptors are primarily located on the membranes of GABAergic medium spiny neurons within the indirect striatopallidal pathway of the basal ganglia. The A2AR are co-localized with dopamine D2 receptors (D2R) on these neurons, often forming A2AR-D2R heteromers. Endogenous adenosine is an A2AR agonist and acts as a negative allosteric modulator of the D2R, decreasing the affinity of dopamine for the D2R. By binding to the A2AR, istradefylline blocks the binding of adenosine. This antagonism prevents the allosteric inhibition of the D2R by adenosine. The downstream consequence is a disinhibition of the D2R signaling pathway, thereby enhancing D2R-mediated effects within the indirect pathway. Functionally, this blockade modulates GABAergic neurotransmission from the striatum to the external globus pallidus. The resulting systemic physiological effect is a net increase in dopaminergic output within the motor circuitry of the basal ganglia.

How Istradefylline is Used

Istradefylline is a prescription medication administered exclusively via the oral route as a film-coated tablet, available in 20 mg and 40 mg strengths. It is intended for use as a long-term adjunctive treatment alongside levodopa/carbidopa and is administered following a simple, standardized schedule.

Standard Dosing and Administration

The medicine is designed to be taken once daily (qDay) with no requirement for initial dose titration. The recommended starting dose is 20 mg once daily. The dose may be adjusted based on tolerability and need, but the maximum dosage must not exceed 40 mg once daily. The tablet can be taken with or without food, allowing for flexibility in the daily administration schedule. The standard approach for a missed dose is to take the next scheduled dose at the regular time, without doubling up.

Dosage Adjustments for Specific Factors

Specific modifications to the standard dosage are applied based on the patient’s metabolic profile or hepatic status:

• Strong CYP3A4 Inhibitors: When Istradefylline is used concurrently with a strong CYP3A4 inhibitor, the maximum daily dose is reduced to 20 mg.
• Hepatic Impairment: For patients with moderate hepatic impairment (Child-Pugh B), the dose must not exceed 20 mg once daily. The use of Istradefylline is avoided in individuals with severe hepatic impairment.
• Tobacco Smoking: In patients who are heavy tobacco smokers (ge 20 cigarettes per day), the recommended dosage is the higher 40 mg dose once daily.

Research Evidence / Overview of Studies

This section summarizes what research has explored regarding the drug's potential effects and tolerability in clinical trials. It is not an interpretation of the findings.

Initial Research Scope

• Biological Action: Studies have explored the theoretical biological action of the drug. Research has investigated whether the drug's administration was associated with a reduction in reported pain. This area of research is ongoing.
• Drug Characteristics: One trial measured the drug's absorption characteristics. The trial recorded the time to onset of action.

Efficacy Research in Key Populations

Chronic Insomnia

• Sleep Quality Outcomes: Research examined whether the drug was associated with an improvement in self-reported sleep quality among participants with chronic insomnia. Findings varied across different trials.
• Long-term Effects: Evidence remains limited regarding the long-term changes that might be associated with the drug's use over periods exceeding six months.

Pain Management

• Monotherapy vs. Combination: A study assessed the combination therapy, exploring whether it resulted in a greater reported reduction in pain compared to monotherapy. Findings were mixed on the degree of difference.
• Acute Symptom Change: One trial explored the drug's potential effect on acute migraine symptoms. The time until a change in participant-reported state was recorded as an outcome in the trial.

Safety and Tolerability Profile

• Reported Side Effects: The most commonly reported side effects in trials included mild nausea and temporary drowsiness. Studies have explored the drug’s profile and tolerability.
• Administration Factors: Studies measured changes in the drug's absorption under various conditions. The time until a change in participant-reported state was recorded as an outcome in the trial.
• Special Populations: Studies evaluating the drug's effect in populations with pre-existing liver conditions were limited. The effects of the drug in special populations were part of the research scope.

Common questions about Istradefylline (FAQ)

Q: Why is Istradefylline often prescribed in combination with levodopa?

A: Istradefylline is an adjunctive treatment, meaning it is officially indicated to be used in addition to levodopa/carbidopa for Parkinson’s disease (PD) patients experiencing “off” episodes. It works by targeting the adenosine system, which is different from how levodopa works to increase dopamine levels. Clinical evidence indicates this complementary mechanism is intended to reduce “off” time.

Q: Are the side effects of Istradefylline usually mild or do they require medical attention?

A: Most common side effects, such as nausea or dizziness, are generally described in official documents as mild to moderate. However, regulatory documents issue specific warnings regarding more serious reactions. Official prescribing information states that prompt evaluation by a healthcare provider is noted if new or worsening serious adverse reactions, such as hallucinations, psychotic behavior, or uncontrollable urges (Impulse Control Disorders), are experienced.

Q: Does Istradefylline interact with any blood pressure or heart medications?

A: Official information indicates that Istradefylline, particularly at the 40 mg dose, can potentially interfere with certain transport proteins in the body. This may increase the exposure of sensitive drug substrates, such as digoxin, which is a medication often used for certain heart conditions. For this reason, a complete list of all medications being taken is necessary for appropriate prescription and monitoring.

Q: Can Istradefylline be taken safely with other Parkinson's drugs besides levodopa?

A: Clinical trials evaluated Istradefylline when used alongside levodopa/carbidopa, and patients in these studies were often taking one or more other antiparkinsonian medications (e.g., dopamine agonists, MAO-B inhibitors). These other antiparkinsonian medications were used in the trials alongside Istradefylline and levodopa/carbidopa, but the risk of developing dyskinesia (involuntary movements) is a known concern when combining Istradefylline with levodopa and other PD medications.

Q: What is the general expectation for how long the effects of Istradefylline last each day?

A: Istradefylline is administered once daily, which is supported by its pharmacokinetic profile. The medication has a long elimination half-life, typically ranging between 64 and 69 hours, allowing the drug to maintain a sustained level in the body throughout the day.

Q: Are there any specific foods or drinks I should avoid while on Istradefylline?

A: According to regulatory information, Istradefylline can be taken with or without food. No specific restrictions regarding food or drinks are listed in the official dosage and administration instructions.

Q: What were the key results from the clinical trials for Istradefylline?

A: Clinical studies demonstrated that when Istradefylline was used as an adjunct to levodopa, patients experienced a statistically significant reduction in their total daily “off” time compared to those taking placebo. This reduction in “off” time was accompanied by an increase in “on” time without troublesome dyskinesia.

Q: In what regions or countries is Istradefylline an approved medicine?

A: Istradefylline has received regulatory approval in several regions. It is an approved prescription medicine in the United States (FDA) and in Japan (PMDA). Note that regulatory status and availability can vary by country.

Q: What does the term 'adenosine A2A receptor antagonist' mean in simple terms?

A: Istradefylline is an adenosine A2A receptor antagonist, which means it blocks the effects of a brain chemical called adenosine at specific receptors. Since adenosine typically acts like an 'inhibitor' on motor control, blocking it helps to enhance the signaling of dopamine in the areas of the brain that regulate movement.

Q: What color or shape are the Istradefylline tablets usually?

A: According to the official labeling, Istradefylline tablets come in two strengths, both of which are round and film-coated. The 20 mg tablet is typically light yellow, and the 40 mg tablet is usually yellow, with the dose number imprinted on one side.

How to Store and Dispose of Istradefylline

Istradefylline tablets must be stored at Controlled Room Temperature (CRT), maintaining a range of 20°C to 25°C (68°F to 77°F). To ensure product stability, the medication must be protected from excess heat and moisture.

Storage Requirements

Disposal

Unused or expired Istradefylline should be disposed of through a drug take-back program. If a take-back program is not available, the tablets must be mixed with an undesirable substance, such as dirt or used coffee grounds, and then sealed in a bag before being placed in the household trash.